Leveraging NGS to Enable Scalable QC & Process Control for Complex Multivariant mRNA Vaccines
9:00 am - Wednesday 30th September 2026
- Exploring how NGS can consolidate multiple critical quality attributes into a single, data-rich analytical workflow for complex mRNA products
- Overcoming the QC and CMC challenges associated with 22-component multivariant RNA vaccines where traditional analytical methods struggle to assess integrity, identity & potency at scale
- Sharing lessons learned from implementing next-generation sequencing approaches for in-process control, release testing & regulatory readiness in next-generation mRNA vaccine development
